This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 May;10(5):397-9.

doi: 10.1016/S1474-4422(11)70075-8. Epub 2011 Apr 8.

PET and 18F ligands in the diagnosis of Alzheimer's disease

Giovanni B Frisoni¹

Affiliations

PMID: 21481641
DOI: 10.1016/S1474-4422(11)70075-8

Comment

PET and 18F ligands in the diagnosis of Alzheimer's disease

Giovanni B Frisoni. Lancet Neurol. 2011 May.

. 2011 May;10(5):397-9.

doi: 10.1016/S1474-4422(11)70075-8. Epub 2011 Apr 8.

Author

Giovanni B Frisoni¹

Affiliation

¹ IRCCS Fatebenefratelli, Brescia, Italy.

PMID: 21481641
DOI: 10.1016/S1474-4422(11)70075-8

No abstract available

PubMed Disclaimer

Comment on

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group. Barthel H, et al. Lancet Neurol. 2011 May;10(5):424-35. doi: 10.1016/S1474-4422(11)70077-1. Epub 2011 Apr 8. Lancet Neurol. 2011. PMID: 21481640 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information